Key Stats for Intuitive Surgical Stock
- Past-Week Performance: -2.7%
- 52-Week Range: $425 to $603.9
- Current Price: $506.2
What Happened?
Intuitive Surgical (ISRG) posted $10.1 billion in 2025 revenue, up 21%, as its da Vinci ecosystem, the gold standard for minimally invasive procedures, treated more than 3.1 million patients globally.
On January 22, Intuitive reported Q4 adjusted EPS of $2.53 against a $2.26 consensus estimate, with worldwide procedure volume, the core demand signal for its instrument-and-accessory revenue stream, rising 18% in the quarter.
The da Vinci 5, its newest flagship surgical robot featuring Force Feedback technology that lets surgeons physically sense tissue resistance, drove 303 of 532 total system placements in Q4, while the installed base crossed 11,100 systems globally, up 12%.
Dave Rosa, CEO, stated on the Q4 2025 earnings call that “da Vinci 5 continues to expand to new indications and geographies,” directly referencing the January 26 FDA cardiac clearance that opens an estimated 160,000-procedure annual opportunity in the U.S. and Korea alone.
With $2.5 billion in free cash flow generated in 2025, $2.3 billion deployed in buybacks, direct European operations now live across Italy, Spain, and Portugal following the March 2 acquisition close, and cardiac and ambulatory surgery center expansion ahead, Intuitive’s growth runway extends well beyond its current $490 share price.
Wall Street’s Take on ISRG Stock
The March 2 acquisition close in Southern Europe, adding 470-plus installed da Vinci systems and 250 employees under direct Intuitive control, converts a distributor margin into a first-party revenue stream across Italy, Spain, and Portugal.
Revenue grew from $8.4 billion in 2024 to $10.1 billion in 2025, a 20.5% jump, and forward estimates project $11.5 billion in 2026 and $13.1 billion in 2027 as procedure volume compounds across three expanding platforms.
Normalized EPS reached $8.93 in 2025, up 21.7%, and the TIKR model projects $10.02 in 2026 and $11.44 in 2027, a trajectory driven by instrument and accessory revenue that scales automatically as the 11,100-system installed base grows.
Analysts covering ISRG show 16 buys, 8 outperforms, 10 holds, and 2 sells among 31 estimates, with a mean price target of $609.82 implying 24.4% upside from the current $490.16 close.
The spread between the street’s $378 low target and $750 high target reflects two genuine fork-in-the-road risks: China competitive erosion and tariff headwinds on one end, and cardiac plus ASC volume inflection on the other.
What Does the Valuation Model Say?
TIKR’s mid-case model prices ISRG at $906.68 by December 2030, implying an 85% total return and a 13.6% annualized IRR, anchored to a 12.5% revenue CAGR and a 32.9% net income margin assumption.
The market is pricing ISRG near a 52-week low of $425 as if procedure growth is decelerating permanently, yet the TIKR model requires only a modest step-down from 20.5% historical revenue growth to 12.5% to generate that $906 target.
The January 26 FDA cardiac clearance for da Vinci 5 opens an estimated 160,000-procedure annual opportunity in the U.S. and Korea alone, a market that generated just 17,000 procedures in 2025 and has nowhere to go but up.
Dave Rosa stated on the Q4 2025 earnings call that “we continue to believe we are in the early stages of this journey,” a claim backed by a line-of-sight procedure opportunity that grew from 7 million in 2024 to 9 million in 2026.
The primary risk to the TIKR model is China, where provincial tenders increasingly favor local robotic suppliers, win ratios fell in Q4, and only 273 system quota slots remain, threatening the OUS growth rate that underpins the 12.5% revenue CAGR assumption.
The Japan reimbursement decision expected in June from the Ministry of Health, Labour and Welfare, covering additional robotic procedures, is the single near-term binary event that confirms or challenges the OUS procedure growth rate embedded in the 2026 guidance range of 13% to 15%.
Should You Invest in Intuitive Surgical, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ISRG stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Intuitive Surgical, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ISRG stock on TIKR for Free →
